Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trinity Biotech has restructured its business activities. The main elements include reorganization of the worldwide sales and marketing function, streamlining the hemostasis and infectious diseases product lines, increased focus within R&D, closure of the Swedish manufacturing facility and a headcount reduction resulting in payroll savings of $5 million.
Subscribe to our email newsletter
In order to optimize its selling effort, Trinity Biotech has decided to reorganize its sales and marketing function into two divisions, the clinical laboratory division and the point-of-care division.
Trinity has carried out a review of its product offering within its two key product lines of hemostasis and infectious diseases. The company has decided to cull a total of 106 hemostasis and 69 infectious diseases products. The result of the product rationalization is that in the future the company will sell 79 hemostasis products, compared to 185 in the past with a negligible impact on revenues. The newly consolidated range of products will be launched under the new Trini brand during 2008.
The company has also decided to focus on a smaller number of projects, with a particular focus on those which will make the greatest contribution to the strategic growth and development of the company and with a view to ensuring that they are delivered on time and within budget. Consequently, the company has decided to suspend development of a number of on-going projects, the two most significant being a HIV over-the-counter product and the development of a HIV Western Blot confirmatory test.